REHOVOT, Israel —July 14, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, hosted a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021.

The webinar featured a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who discussed New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX’s management gave an update on their Tumor Targeted Superantigen (TTS) platform’s lead candidate, naptumomab estafenatox (NAP) in overcoming resistance. NAP is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management answered questions following the formal presentations.

To watch the webinar recording, please click here.

 About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information,

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com